Article
Genetics & Heredity
Justine Marsolier, Pacome Prompsy, Adeline Durand, Anne-Marie Lyne, Camille Landragin, Amandine Trouchet, Sabrina Tenreira Bento, Almut Eisele, Sophie Foulon, Lea Baudre, Kevin Grosselin, Mylene Bohec, Sylvain Baulande, Ahmed Dahmani, Laura Sourd, Eric Letouze, Anne-Vincent Salomon, Elisabetta Marangoni, Leila Perie, Celine Vallot
Summary: The persistence of drug-resistant cancer cells is a major clinical challenge, particularly in triple-negative breast cancer. This study reveals that the repressive histone mark H3K27me3 plays a crucial role in regulating cell fate and chemotherapy tolerance in cancer cells. Manipulating H3K27me3 levels effectively enhances the potential of cancer cells to tolerate chemotherapy and delays tumor recurrence. These findings underscore the importance of understanding chromatin landscapes in shaping cancer cell response to initial therapy.
Article
Biochemistry & Molecular Biology
Lijuan Guo, Wanjun Zhang, Xue Zhang, Jun Wang, Jiaqi Nie, Xiaomeng Jin, Ying Ma, Shi Wang, Xinhong Zhou, Yilei Zhang, Yan Xu, Yoshimasa Tanaka, Jingping Yuan, Xing-Hua Liao, Yiping Gong, Li Su
Summary: In this study, SIPA1 was found to function as a transcription factor that regulates the expression of genes involved in cell growth, differentiation, and response to environmental factors. Importin β1 was identified as an interacting partner of SIPA1 during fibronectin treatment. SIPA1's DNA-binding region (DBR) recognized and bound to a TGAGTCAB motif, and its transcriptional regulation was shown to be necessary for the migration and invasion of triple-negative breast cancer cells.
Article
Multidisciplinary Sciences
Jiahui Xu, Xiaoli Yang, Qiaodan Deng, Cong Yang, Dong Wang, Guojuan Jiang, Xiaohong Yao, Xueyan He, Jiajun Ding, Jiankun Qiang, Juchuanli Tu, Rui Zhang, Qun-Ying Lei, Zhi-min Shao, Xiuwu Bian, Ronggui Hu, Lixing Zhang, Suling Liu
Summary: Enhanced neovasculogenesis, especially vasculogenic mimicry (VM), contributes to the development of triple-negative breast cancer (TNBC). We identified TEM8 as a functional marker for VM-forming BTICs in TNBC, providing a target for the development of effective therapies against TNBC targeting both BTIC self-renewal and neovasculogenesis simultaneously. TEM8 promotes stemness and VM differentiation capacity through a RhoC/ROCK1/SMAD5 axis.
NATURE COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Selase Ativui, Cynthia A. Danquah, Paul Poku Sampene Ossei, Michael Ofori
Summary: This study demonstrated that palmatine has the potential to improve hypoxemia, ameliorate metastasis-associated lung injury, decrease lung MTA1 expression, and increase p53 expression in the treatment of lung metastasis from triple negative breast cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Materials Science, Multidisciplinary
Qingxin Mu, Guanyou Lin, Mike Jeon, Hui Wang, Fei-Chien Chang, Richard A. Revia, John Yu, Miqin Zhang
Summary: This study presents a multifunctional nanoparticle formulation targeting TNBC cells and dendritic cells, inducing tumor apoptosis through multiple mechanisms and significantly inhibiting tumor growth and metastasis while extending survival in a drug-resistant mouse model of TNBC. The promising platform may substantially improve therapeutic efficacy for treating metastatic TNBC.
Review
Oncology
Hussein Sabit, Emre Cevik, Huseyin Tombuloglu, Shaimaa Abdel-Ghany, Guzin Tombuloglu, Manel Esteller
Summary: This review elucidates the role of miRNAs in triple negative breast cancer (TNBC), categorizing them based on specific mechanisms in TNBC. The study highlights the importance of accurate diagnosis, prognosis, and treatment approaches for this aggressive subtype of breast cancer, summarizing the most up-to-date findings in miRNA profiling and therapeutic strategies.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Pharmacology & Pharmacy
Jun Zhang, Yu Xia, Xiaomei Zhou, Honghao Yu, Yufang Tan, Yaying Du, Qi Zhang, Yiping Wu
Summary: Triple-negative breast cancer is a highly malignant subtype of breast cancer with aggressive behaviors. It is associated with poor clinical outcomes, early recurrence, and a higher likelihood of visceral metastases compared to other types of breast cancer. Personalized or combined therapies based on molecular heterogeneity are showing promising results in treating triple-negative breast cancer.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Kurt W. Evans, Erkan Yuca, Stephen S. Scott, Ming Zhao, Natalia Paez Arango, Christian X. Cruz Pico, Turcin Saridogan, Maryam Shariati, Caleb A. Class, Christopher A. Bristow, Christopher P. Vellano, Xiaofeng Zheng, Ana Maria Gonzalez-Angulo, Xiaoping Su, Coya Tapia, Ken Chen, Argun Akcakanat, Bora Lim, Debu Tripathy, Timothy A. Yap, Maria Emilia Di Francesco, Giulio F. Draetta, Philip Jones, Timothy P. Heffernan, Joseph R. Marszalek, Funda Meric-Bernstam
Summary: Oxidative phosphorylation is a metabolic vulnerability in triple-negative breast cancer, and inhibiting it with IACS-10759 may enhance efficacy of multiple targeted therapies.
Article
Cell Biology
Zeyu Xing, Ruojiao Wang, Xin Wang, Jiaqi Liu, Menglu Zhang, Kexin Feng, Xiang Wang
Summary: The study demonstrated that circPDCD11 functions as an oncogene in triple-negative breast cancer (TNBC), promoting metabolic activity and tumor growth. This circRNA serves as a miRNA sponge to upregulate LDHA expression, providing a potential prognostic biomarker for TNBC.
CELL DEATH DISCOVERY
(2021)
Article
Oncology
Yanlin Li, Tiantian Wu, Ziluo Peng, Xianyan Tian, Qian Dai, Miao Chen, Jun Zhu, Song Xia, Aiqin Sun, Wannian Yang, Qiong Lin
Summary: ETS1 is highly expressed in breast tumor tissues, specifically associated with tumor metastasis and poor survival in TNBC. Depletion of ETS1 inhibited cell proliferation and migration in TNBC cells by downregulating YAP and its target genes.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Eriko Katsuta, Kazuaki Takabe, Marija Vujcic, Philip A. Gottlieb, Tao Dai, Arnaldo Mercado-Perez, Arthur Beyder, Qingfei Wang, Mateusz Opyrchal
Summary: High expression of PIEZO2 in breast cancer, particularly in triple-negative breast cancer (TNBC), is associated with worse clinical outcomes. Activation of PIEZO2 leads to increased cell motility and invasive phenotypes, as well as the upregulation of epithelial-mesenchymal transition (EMT)-related genes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Lili Gao, Junzhe Zhang, Qianqian Long, Yang Yang, Yiming Li, Guoqiang Li, Peng Pu, Shanshi Tong, Yamin He, Qing Li, Yang Chen, Yingbin Liu, Xianming Kong
Summary: This study reveals a novel pathway, the SETD7/YY1 axis, which regulates epithelial-mesenchymal transition and tumor cell migration via the ERK/MAPK pathway in triple-negative breast cancer (TNBC). These findings suggest a potential therapeutic target for advanced TNBC treatment.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2023)
Article
Immunology
Qin Zhou, Jiawei Xu, Yan Xu, Shaokun Sun, Jian Chen
Summary: The study found that low ICAM1 expression may be related to immune escape, leading to poor treatment response and a worse prognosis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Radhakrishnan Vishnubalaji, Nehad M. Alajez
Summary: TGF beta signaling in TNBC is complex and involves regulation of protein coding genes and long non-coding RNA. The study provides a comprehensive analysis of the transcriptional landscape in response to TGF beta activation and inhibition, revealing potential targets for TGF beta regulation in TNBC.
SCIENTIFIC REPORTS
(2021)